Identification and characterization of small-molecule ligands that maintain pluripotency of human embryonic stem cells

Biochemical Society Transactions

Volumn 38, Issue 4, 2010, Pages 1058-1061

  Burton, Peter ^a   Adams, David R ^b   Abraham, Achamma ^b   Allcock, Robert W ^b   Jiang, Zhong ^b   McCahill, Angela ^a   Gilmour, Jane ^a   McAbney, John ^a   Kane, Nicole M ^c   Baillie, George S ^a   McKenzie, Fergus R ^d   Baker, Andrew H ^c   Houslay, Miles D ^a   Mountford, Joanne C ^a   Milligan, Graeme ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b HERIOT WATT UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d Scottish Enterprise Tayside Region   (United Kingdom)

Author keywords

Adenosine deaminase; Human embryonic stem cell; Phosphodiesterase; Pluripotency

Indexed keywords

[ERYTHRO 9 (2 HYDROXY 3 NONYL)ADENINE]; ADENINE DERIVATIVE; BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; LIGAND; OCTAMER TRANSCRIPTION FACTOR 4; STAGE SPECIFIC EMBRYO ANTIGEN 4; TRANSCRIPTION FACTOR NANOG; UNCLASSIFIED DRUG;

CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CONCENTRATION RESPONSE; DRUG ACTIVITY; EMBRYONIC STEM CELL; HUMAN; NONHUMAN; PARTICLE SIZE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; SCREENING; SHORT SURVEY; SYNTHESIS;

CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; EMBRYONIC STEM CELLS; HUMANS; LIGANDS; PLURIPOTENT STEM CELLS; SMALL MOLECULE LIBRARIES;

EID: 77955979078     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST0381058     Document Type: Short Survey

References (30)

1. Reubinoff, B.E., Pera, M.F., Fong, C.Y., Trounson, A. and Bongso, A. (2000) Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat. Biotechnol. 18, 399-404
2. Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A., Swiergiel, J.J., Marshall, V.S. and Jones, J.M. (1998) Embryonic stem cell lines derived from human blastocysts. Science 282, 1145-1147
3. Jensen, J., Hyllner, J. and Björquist, P. (2009) Human embryonic stem cell technologies and drug discovery. J. Cell Physiol. 219, 513-519
4. Nirmalanandhan, V.S. and Sittampalam, G.S. (2009) Stem cells in drug discovery, tissue engineering, and regenerative medicine: emerging opportunities and challenges. J. Biomol. Screen. 14, 755-768
5. Pouton, C.W. and Haynes, J.M. (2007) Embryonic stem cells as a source of models for drug discovery. Nat. Rev. Drug Discov. 6, 605-616
6. Heins, N., Englund, M.C., Sjoblom, C., Dahl, U., Tonning, A., Bergh, C., Lindahl, A., Hanson, C. and Semb, H. (2004) Derivation, characterization, and differentiation of human embryonic stem cells. Stem Cells 22, 367-376
7. Liu, Y., Song, Z., Zhao, Y., Qin, H., Cai, J., Zhang, H., Yu, T., Jiang, S., Wang, G., Ding, M. and Deng, H. (2006) A novel chemical-defined medium with bFGF and N2B27 supplements supports undifferentiated growth in human embryonic stem cells. Biochem. Biophys. Res. Commun. 346, 131-139
8. Houslay, M.D. and Milligan, G. (1997) Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biochem. Sci. 22, 217-224
9. Houslay, M.D. (2010) Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem. Sci. 35, 91-100
10. Houslay, M.D. and Adams, D.R. (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem. J. 370, 1-18
11. Michie, A.M., Lobban, M., Muller, T., Harnett, M.M. and Houslay, M.D. (1996) Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram. Cell. Signalling 8, 97-110
12. Boess, F.G., Hendrix, M., van der Staay, F.J., Erb, C., Schreiber, R., van Staveren, W., de Vente, J., Prickaerts, J., Blokland, A. and Koenig, G. (2004) Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 47, 1081-1092
13. Castro, L.R., Verde, I., Cooper, D.M. and Fischmeister, R. (2006) Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation 113, 2221-2228
14. Lugnier, C. (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol. Ther. 109, 366-398
15. Carson, D.A. and Seegmiller, J.E. (1976) Effect of adenosine deaminase inhibition upon human lymphocyte blastogenesis. J. Clin. Invest. 57, 274-282
16. Antonioli, L., Fornai, M., Colucci, R., Ghisu, N., Da Settimo, F., Natale, G., Kastsiuchenka, O., Duranti, E., Virdis, A., Vassalle, C. et al. (2007) Inhibition of adenosine deaminase attenuates inflammation in experimental colitis. J. Pharmacol. Exp. Ther. 322, 435-442
17. Di Iorio, P., Kleywegt, S., Ciccarelli, R., Traversa, U., Andrew, C.M., Crocker, C.E., Werstiuk, E.S. and Rathbone, M.P. (2002) Mechanisms of apoptosis induced by purine nucleosides in astrocytes. Glia 38, 179-190
18. Hashemi, M., Karami-Tehrani, F., Ghavami, S., Maddika, S. and Los, M. (2005) Adenosine and deoxyadenosine induces apoptosis in oestrogen receptor-positive and -negative human breast cancer cells via the intrinsic pathway. Cell Prolif. 38, 269-285
19. Hershfield, M.S. (2005) New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency Eur. J. Immunol. 35, 25-30
20. Singhal, D. and Anderson, B.D. (1998) Absorption and intestinal metabolism of purine dideoxynucleosides and an adenosine deaminase-activated prodrug of 2′,3′-dideoxyinosine in the mesenteric vein cannulated rat ileum. J. Pharmacol. Sci. 87, 578-585
21. Tofovic, S.P., Zacharia, L., Carcillo, J.A. and Jackson, E.K. (2001) Inhibition of adenosine deaminase attenuates endotoxin-induced release of cytokines in vivo in rats. Shock 16, 196-202
22. Nabhan, C., Gartenhaus, R.B. and and Tallman, M.S. (2004) Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. Leuk. Res. 28, 429-442
23. Lamanna, N. and Kay, N.E. (2009) Pentostatin treatment combinations in chronic lymphocytic leukemia. Clin. Adv. Hematol. Oncol. 7, 386-392
24. Robak, T., Korycka, A., Lech-Maranda, E. and Robak, P. (2009) Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. Molecules 14, 1183-1226
25. Robak, T., Korycka, A., Lech-Maranda, E. and Robak, P. (2007) AMP-activated protein kinase in metabolic control and insulin signaling. Circ. Res. 100, 328-341
26. Wong, A.K., Howie, J., Petrie, J.R. and Lang, C.C. (2009) AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease. Clin. Sci. 116, 607-620
27. Jacobson, K.A. (2009) Introduction to adenosine receptors as therapeutic targets. Handb. Exp. Pharmacol. 193, 1-24
28. Sato, N., Meijer, L., Skaltsounis, L., Greengard, P. and Brivanlou, A.H. (2004) Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat. Med. 10, 55-63
29. Li, J., Wang, G., Wang, C., Zhao, Y., Zhang, H., Tan, Z., Song, Z., Ding, M. and Deng, H. (2007) MEK/ERK signaling contributes to the maintenance of human embryonic stem cell self-renewal. Differentiation 75, 299-307
30. Dvorak, P., Dvorakova, D., Koskova, S., Vodinska, M., Najvirtova, M., Krekac, D. and Hampl, A. (2005) Expression and potential role of fibroblast growth factor 2 and its receptors in human embryonic stem cells. Stem Cells 23, 1200-1211